Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 16;328(7):676-678.
doi: 10.1001/jama.2022.11691.

Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers

Elena Azzolini  1 , Riccardo Levi  2 , Riccardo Sarti  2 , Chiara Pozzi  1 , Maximiliano Mollura  3 , Alberto Mantovani  1 , Maria Rescigno  1
Affiliations

Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers

Elena Azzolini et al. JAMA. .

Abstract

This study examines the risk of long COVID following mRNA vaccination, compared with no vaccination, in health care workers in Italy who had COVID-19 infection.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Mantovani reported receiving personal fees for lectures from Ventana, Novartis, and Roche; consulting fees from Pierre Fabre, Verily, AbbVie, AstraZeneca, Third Rock Venture, and Merck; serving on the advisory board for Verseau Therapeutics, Myeloid Therapeutics, Imcheck Therapeutics, Ellipses, Olatec Therapeutics, Macrophage Pharma, Biovelocita, Principia, and Biolegend; grants from Novartis; and royalties for sale of reagents from Biolegend Royalties, Cedarlane Laboratories, HyCult Biotechnology, eBioscience Royalties, ABCAM Plc, Novus Biologicals, Enzo Life, and Affymetric. Dr Mantovani also reported having a patent for antihuman migration stimulating factor (MSF), a patent for NK or T cells and uses thereof, a patent for "use of SAP for the treatment of Euromycetes fungi infections,” and a patent for PTX3 as prognostic marker in COVID-19 licensed to Diasorin (prospective trial in sepsis underway). Dr Rescigno reported serving on the advisory board (with compensation) for MillBo and receiving grants from AlfaSigma, Gelesis, and Diasorin outside the submitted work. No other disclosures were reported.

References

    1. Groff D, Sun A, Ssentongo AE, et al. . Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. 2021;4(10):e2128568. doi:10.1001/jamanetworkopen.2021.28568 - DOI - PMC - PubMed
    1. Su Y, Yuan D, Chen DG, et al. ; ISB-Swedish COVID-19 Biobanking Unit . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20. doi:10.1016/j.cell.2022.01.014 - DOI - PMC - PubMed
    1. Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis. Published online April 16, 2022. doi:10.1093/infdis/jiac136 - DOI - PMC - PubMed
    1. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. Published online May 25, 2022. doi:10.1038/s41591-022-01840-0 - DOI - PMC - PubMed
    1. Levi R, Azzolini E, Pozzi C, et al. . One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. J Clin Invest. 2021;131(12):149154. doi:10.1172/JCI149154 - DOI - PMC - PubMed